Company Overview

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company advancing a novel and potentially transformative solution for patients with vascular diseases where restricted blood flow and endothelial dysfunction are the primary drivers of disease.

DiaMedica’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases.